Neonatal SepsisNCT00800449
Distribution of Haptoglobin Phenotype in Septic and Non Septic Pre-term Neonates (PTSH)
An observational study of Neonatal Sepsis, run by Irina Kessel at 1 site in Israel.
Trial summary
The Haptoglobin (Hp) gene locus at chromosome 16q22 is polymorphic with two alleles denoted 1 and 2 .The gene product exists in three phenotypes: 1-1, 2-1, and 2-2. The Haptoglobin 2 allele is found only in man and is believed to have arisen from the Haptoglobin 1 allele by a partial intragenic duplication. Read more about this study
- Who is it for?
- Ages 24 to 35 weeks
- Conditions the study is for
- Neonatal Sepsis
- How many people
- 133 participants
- Where
- 1 siteIsrael
- Study dates
- Aug 2007to Sep 2011
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 24 to 35 weeks
- All sexes
- No healthy volunteers
- Child
Study population: All preterm neonates ( a total of 150 preterm babies, 35 weeks or younger) admitted to the NICU in Carmel hospital.
Who may be able to join
- Preterm babies born at 35 week gestational age and younger being admitted to the preterm unit in Carmel Medical Center over a period of one year.
Who cannot join
- Pre-term neonates with serious congenital defects.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Prospective Assessment of the Distribution of Haptoglobin Phenotype in Septic and Non Septic Pre-term Neonates (PTSH)
The Haptoglobin (Hp) gene locus at chromosome 16q22 is polymorphic with two alleles denoted 1 and 2 .The gene product exists in three phenotypes: 1-1, 2-1, and 2-2.
The Haptoglobin 2 allele is found only in man and is believed to have arisen from the Haptoglobin 1 allele by a partial intragenic duplication. Haptoglobin 2 allele frequency is higher than the Haptoglobin 1 allele. It has been hypothesized that the Haptoglobin 2 allele was spread in man due to its selective advantage against life-threatening infections.
Read more
In vitro, only the Haptoglobin 2 allele protein, binds to the streptococcus T antigen, resulting in its aggregation and slowing its growth .
Individuals homozygous for the Haptoglobin 1 allele (1-1 genotype) are more prone to the streptococcal infection than individuals with the Haptoglobin 2 allele(2-1 or 2-2 genotype).
The investigators wish to explore the linkage between Hp phenotype and sepsis in pre-term neonates, considering that in this early stage in life, genetic properties which provide a defense against infectious agents will be of heightened importance.
Read the detailed description
The Haptoglobin (Hp) gene locus at chromosome 16q22 is polymorphic with two alleles denoted 1 and 2 .The gene product exists in three phenotypes: 1-1, 2-1, and 2-2. Hp 2 allele DM individuals have larger myocardial infarctions than homozygous Hp 1 DM individuals. This may be due to differences in the antioxidant and anti-inflammatory properties of these proteins.The same phenomenon was demonstrated in a murine coronary ischemia-reperfusion model.
The Haptoglobin is an acute phase protein with anti-oxidant, bacteriostatic and anti-inflammatory functions.
The Haptoglobin 2 allele is found only in man and is believed to have arisen from the Haptoglobin 1 allele by a partial intragenic duplication. Haptoglobin 2 allele frequency is higher than the Haptoglobin 1 allele. It has been hypothesized that the Haptoglobin 2 allele was spread in man due to its selective advantage against life-threatening infections.
In vitro, only the Haptoglobin 2 allele protein, binds to the streptococcus T antigen, resulting in its aggregation and slowing its growth .
We proposed that in individuals homozygous for the Haptoglobin 1 allele (1-1 genotype), the streptococcal infection would be more severe than in individuals with the Haptoglobin 2 allele (2-1 or 2-2 genotype).
During a severe outbreak of impetigo in two infantry units in the Israeli Defense Forces, over 60% (57/91) of the soldiers developed impetigo caused by a single pathogen-group A streptococcus. 33% of them developed serious life-threatening complications requiring hospitalization. The risk of Haptoglobin 1-1 genotype individuals developing severe infection was significantly higher than individuals with Haptoglobin 2 genotype (45.5% (5/11) vs. 17.5% (14/80), risk ratio 2.6 (95% confidence interval 1.2-5.8), p=0.05). This supports the notion that the Haptoglobin genotype determines the susceptibility to streptococcus infection, an important pathogen early in human evolution, and explains the spread of Haptoglobin 2 allele in human.
Another study demonstrated that Diabetic dialysis patients at the age of 60 and above carrying the Hp1-1 phenotype had a lower mortality rate compared to the patients who are Hp2-2. However, younger population has shown the opposite. This can be explained by the survivorship pattern of Hp1-1 diabetic patients who have lower risk for diabetic complications. They will also survive dialysis in older age by suffering less from vascular complications compared to Hp2-2. However, in Hp2-2 younger patients, the infectious parameter is more significant and mortality will be lower.
We wish to explore the linkage between Hp phenotype and sepsis in pre-term neonates, considering that in this early stage in life, genetic properties which provide a defense against infectious agents will be of heightened importance.
During the study period of one year, all preterm neonates (a total of 150 preterm babies, 35 weeks or younger) admitted to the preterm unit at Carmel hospital will be typed for Hp phenotype by a blood test. Hp phenotyping needs only about 500 microliters of blood which will be taken during routine blood drawn. All blood samples will be identified with the patient's I.D. number and name in addition to the study consecutive serial number. The blood samples will be sent to the laboratory of vascular medicine in the faculty of medicine at the Technion. If the number of participating infants during one year will be insufficient (less than 150), we will ask for additional permission of the ethical committee to continue the study for the second year.
Septic neonates will be recognized by clinical deterioration (abnormal body temperature and/or disturbed skin perfusion and/or apathy and/or increase in apnea/bradycardia episodes and/or abnormal CBC, leukocytosis or leucopenia or left shift or thrombocytopenia) and concomitant positive blood cultures, without another explanation of non infectious etiology. Details of the bacteria including antibiotic resistance profile will be documented. Demographic data will be collected for all patients.
In addition data regarding known pre-maturity complications such as Retinopathy of Pre-maturity (ROP), Necrotizing Entero-Colitis (NEC), Broncho-Pulmonary Dysplasia (BPD) will be assessed and documented according to the admission summary.
Blood transport, Hp typing and data collection will be done by a MD student as part of her MD thesis.
As part of the informed consent, we will ask the permission for a possible follow up one year after discharge from the hospital which will be done by a phone questionnaire and acquiring the patients medical file data with the help of his family
- Conditions
- Neonatal Sepsis
- Keywords
- Haptoglobin, sepsis, premature babies
- Medical subject headings
- Neonatal Sepsis, Sepsis, Premature Birth
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Dec 2008 (estimated)
- Study startAug 2007
- Primary completionMar 2011
- Study completionSep 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neonatal SepsisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 133 participants (actual)
Sponsor and investigators
- Lead sponsor
- Irina Kessel
- Sponsor type
- University, hospital or other
- Collaborators
- Carmel Medical Center, Technion, Israel Institute of Technology
- Responsible party
- Sponsor-investigator, Irina Kessel, Carmel Medical Center
- Investigators
- Irena Kessel, MD, Principal investigator, Carmel Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00800449
- Sponsor's protocol ID
- PTSH001
- Status last verified
- Feb 2012
- First submitted
- 30 Nov 2008
- Last updated
- 14 Feb 2012
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 14 Feb 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Assessment of the Distribution of Haptoglobin Phenotype in Septic and Non Septic Pre-term Neonates (PTSH)
- ClinicalTrials.gov ID
- NCT00800449
- Acronym / sponsor ID
- PTSH001
- Conditions
- Neonatal Sepsis
- Keywords
- Haptoglobin, sepsis, premature babies
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 133 participants (actual)
- Lead sponsor
- Irina KesselUniversity, hospital or other
- Collaborators
- Carmel Medical Center, Technion, Israel Institute of Technology
- Study start
- Aug 2007
- Primary completion
- Mar 2011 (actual)
- Study completion
- Sep 2011 (actual)
- First posted
- 2 Dec 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Haptoglobin (Hp) gene locus at chromosome 16q22 is polymorphic with two alleles denoted 1 and 2 .The gene product exists in three phenotypes: 1-1, 2-1, and 2-2.
The Haptoglobin 2 allele is found only in man and is believed to have arisen from the Haptoglobin 1 allele by a partial intragenic duplication. Haptoglobin 2 allele frequency is higher than the Haptoglobin 1 allele. It has been hypothesized that the Haptoglobin 2 allele was spread in man due to its selective advantage against life-threatening infections.
In vitro, only the Haptoglobin 2 allele protein, binds to the streptococcus T antigen, resulting in its aggregation and slowing its growth .
Individuals homozygous for the Haptoglobin 1 allele (1-1 genotype) are more prone to the streptococcal infection than individuals with the Haptoglobin 2 allele(2-1 or 2-2 genotype).
The investigators wish to explore the linkage between Hp phenotype and sepsis in pre-term neonates, considering that in this early stage in life, genetic properties which provide a defense against infectious agents will be of heightened importance.
Detailed description
The Haptoglobin (Hp) gene locus at chromosome 16q22 is polymorphic with two alleles denoted 1 and 2 .The gene product exists in three phenotypes: 1-1, 2-1, and 2-2. Hp 2 allele DM individuals have larger myocardial infarctions than homozygous Hp 1 DM individuals. This may be due to differences in the antioxidant and anti-inflammatory properties of these proteins.The same phenomenon was demonstrated in a murine coronary ischemia-reperfusion model.
The Haptoglobin is an acute phase protein with anti-oxidant, bacteriostatic and anti-inflammatory functions.
The Haptoglobin 2 allele is found only in man and is believed to have arisen from the Haptoglobin 1 allele by a partial intragenic duplication. Haptoglobin 2 allele frequency is higher than the Haptoglobin 1 allele. It has been hypothesized that the Haptoglobin 2 allele was spread in man due to its selective advantage against life-threatening infections.
In vitro, only the Haptoglobin 2 allele protein, binds to the streptococcus T antigen, resulting in its aggregation and slowing its growth .
We proposed that in individuals homozygous for the Haptoglobin 1 allele (1-1 genotype), the streptococcal infection would be more severe than in individuals with the Haptoglobin 2 allele (2-1 or 2-2 genotype).
During a severe outbreak of impetigo in two infantry units in the Israeli Defense Forces, over 60% (57/91) of the soldiers developed impetigo caused by a single pathogen-group A streptococcus. 33% of them developed serious life-threatening complications requiring hospitalization. The risk of Haptoglobin 1-1 genotype individuals developing severe infection was significantly higher than individuals with Haptoglobin 2 genotype (45.5% (5/11) vs. 17.5% (14/80), risk ratio 2.6 (95% confidence interval 1.2-5.8), p=0.05). This supports the notion that the Haptoglobin genotype determines the susceptibility to streptococcus infection, an important pathogen early in human evolution, and explains the spread of Haptoglobin 2 allele in human.
Another study demonstrated that Diabetic dialysis patients at the age of 60 and above carrying the Hp1-1 phenotype had a lower mortality rate compared to the patients who are Hp2-2. However, younger population has shown the opposite. This can be explained by the survivorship pattern of Hp1-1 diabetic patients who have lower risk for diabetic complications. They will also survive dialysis in older age by suffering less from vascular complications compared to Hp2-2. However, in Hp2-2 younger patients, the infectious parameter is more significant and mortality will be lower.
We wish to explore the linkage between Hp phenotype and sepsis in pre-term neonates, considering that in this early stage in life, genetic properties which provide a defense against infectious agents will be of heightened importance.
During the study period of one year, all preterm neonates (a total of 150 preterm babies, 35 weeks or younger) admitted to the preterm unit at Carmel hospital will be typed for Hp phenotype by a blood test. Hp phenotyping needs only about 500 microliters of blood which will be taken during routine blood drawn. All blood samples will be identified with the patient's I.D. number and name in addition to the study consecutive serial number. The blood samples will be sent to the laboratory of vascular medicine in the faculty of medicine at the Technion. If the number of participating infants during one year will be insufficient (less than 150), we will ask for additional permission of the ethical committee to continue the study for the second year.
Septic neonates will be recognized by clinical deterioration (abnormal body temperature and/or disturbed skin perfusion and/or apathy and/or increase in apnea/bradycardia episodes and/or abnormal CBC, leukocytosis or leucopenia or left shift or thrombocytopenia) and concomitant positive blood cultures, without another explanation of non infectious etiology. Details of the bacteria including antibiotic resistance profile will be documented. Demographic data will be collected for all patients.
In addition data regarding known pre-maturity complications such as Retinopathy of Pre-maturity (ROP), Necrotizing Entero-Colitis (NEC), Broncho-Pulmonary Dysplasia (BPD) will be assessed and documented according to the admission summary.
Blood transport, Hp typing and data collection will be done by a MD student as part of her MD thesis.
As part of the informed consent, we will ask the permission for a possible follow up one year after discharge from the hospital which will be done by a phone questionnaire and acquiring the patients medical file data with the help of his family
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 24 to 35 weeks
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- All preterm neonates ( a total of 150 preterm babies, 35 weeks or younger) admitted to the NICU in Carmel hospital.
Key inclusion criteria (1 listed)
- Preterm babies born at 35 week gestational age and younger being admitted to the preterm unit in Carmel Medical Center over a period of one year.
Key exclusion criteria (1 listed)
- Pre-term neonates with serious congenital defects.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Feb 2012.
Related trials for Neonatal Sepsis
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
RecruitingPhase 1
NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
Chronic Granulomatous Disease, Infection
RecruitingPhase 3
Selective Antibiotics When Symptoms Develop Versus Universal Antibiotics for Preterm Neonates
Sepsis, PROM, Preterm (Pregnancy)
Not yet recruiting
G-CSF In Neonatal Sepsis With Neutropenia
Neonatal Sepsis, Neutropenia
Not yet recruitingEarly Phase 1
25BT056: Basket Study of Viral Cytotoxic T Lymphocytes
EBV Viremia, CMV Viremia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Irena Kessel, MD principal investigator
Carmel Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Neonatal Sepsis, run by Irina Kessel at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Feb 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Feb 2012.